8-K
filed November 7, 2024, 6:59 PM ET
CIK 0001900520
M&A
confidence high
sentiment neutral
materiality 0.90
Lomond Therapeutics Holdings, Inc.: M&A transaction — SPAC Venetian-1 completes reverse merger with biotech Lomond; raises $43.9M in PIPE
Lomond Therapeutics Holdings, Inc.
- Merger closed Nov 1, 2024; Venetian-1 changed name to Lomond Therapeutics Holdings, Inc.
- Legacy Lomond stockholders received 14,420,383 shares; 3,625,000 pre-merger shares forfeited.
- Private placement raised $43.9M: 8,241,375 shares at $4.00 plus SAFE conversions at $3.20/$3.60.
- Options for 4,329,617 shares at $1.30 assumed; 2024 Equity Incentive Plan adopted.
- Lock-up agreements for directors/officers; company must file resale registration statement within 20 trading days.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Lomond Therapeutics Holdings, Inc.: Amended and restated bylaws in their entirety (effective 2024-11-01).
- Change
- bylaw amendment
- Effective
- 2024-11-01
Exact text from the filing
Amended and Restated Bylaws Prior to the Merger, on November 1, 2024, we amended and restated our bylaws in their entirety.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Lomond Therapeutics Holdings, Inc.: Amended and restated certificate of incorporation (effective 2024-11-01).
- Change
- charter amendment
- Effective
- 2024-11-01
Exact text from the filing
Amended and Restated Certificate of Incorporation Prior to the Merger, our board of directors approved the amendment and restatement of our certificate of incorporation on November 1, 2024, and stockholders holding 100% of the then outstanding shares of our common stock approved the amendment and restatement to our certificate of incorporation on November 1, 2024, which became effective when filed with the Secretary of State of the State of Delaware on November 1, 2024.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Lomond Therapeutics Holdings, Inc.: Ceased to be a shell company as a result of the Merger.
- Change
- shell status
Exact text from the filing
Prior to the Merger, we were a "shell company" (as such term is defined in Rule 12b-2 under the Exchange Act). As a result of the Merger, we have ceased to be a shell company.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Lomond Therapeutics Holdings, Inc. completed an acquisition involving Lomond Therapeutics, Inc. (closed 2024-11-01).
- Action
- acquisition
- Counterparty
- Lomond Therapeutics, Inc.
- Closing
- 2024-11-01
Exact text from the filing
Acquisition Sub merged with and into Legacy Lomond, with Legacy Lomond continuing as the surviving corporation and our wholly-owned subsidiary.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.